The text starts here.

News Release

May 26, 2003

Eisai Submits sNDA for CLEACTORR for Acute Pulmonary Embolism

Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) submitted on May 26 a supplemental New Drug Application (sNDA) for CLEACTORR (generic name: monteplase (r DNA origin)) for treatment of acute pulmonary embolism to the Ministry of Health, Labour and Welfare in Japan.

CLEACTORR was classified as an orphan drug (a medicine for a rare disease) in March 1998. CLEACTORR is expected as the first t-PA (tissue-type plasminogen activator) drug for the indication of acute pulmonary embolism treatment.

CLEACTORR, the second generation t-PA drug, was independently developed by Eisai utilizing recombinant DNA techniques. The administration of CLEACTORR, when given as a bolus injection, is achieved in about two minutes with an elimination of half-life in blood plasma of greater than 20 minutes. CLEACTORR, was launched with the indication of lysis of coronary thrombus caused by acute myocardial infarction (within 6 hours after onset of symptoms) in June 1998. The company reported sales of about 900 million yen for CLEACTORR for the fiscal year 2002.